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prediction of prostate cancer 
Gleason score upgrading from 
biopsy to radical prostatectomy 
using pre-biopsy multiparametric 
MRi piRADS scoring system
Saeed Alqahtani1,2,5, Cheng Wei1,6, Yilong Zhang2, Magdalena Szewczyk-Bieda3, 
Jennifer Wilson4, Zhihong Huang2 & Ghulam nabi1 ✉
An increase or ‘upgrade’ in Gleason Score (GS) in prostate cancer following transrectal Ultrasound 
(TRUS) guided biopsies remains a significant challenge to overcome. to evaluate whether MRI has 
the potential to narrow the discrepancy of histopathological grades between biopsy and radical 
prostatectomy, three hundred and thirty men treated consecutively by laparoscopic radical 
prostatectomy (LRP) between July 2014 and January 2019 with localized prostate cancer were included 
in this study. Independent radiologists and pathologists assessed the MRI and histopathology of the 
biopsies and prostatectomy specimens respectively. A multivariate model was constructed using 
logistic regression analysis to assess the ability of MRI to predict upgrading in biopsy GS in a nomogram. 
A decision-analysis curve was constructed assessing impact of nomogram using different thresholds 
for probabilities of upgrading. PIRADS scores were obtained from MRI scans in all the included cases. 
In a multivariate analysis, the PIRADS v2.0 score significantly improved prediction ability of MRI scans 
for upgrading of biopsy GS (p = 0.001, 95% CI [0.06–0.034]), which improved the C-index of predictive 
nomogram significantly (0.90 vs. 0.64, p < 0.05). PIRADS v2.0 score was an independent predictor 
of postoperative GS upgrading and this should be taken into consideration while offering treatment 
options to men with localized prostate cancer.
Histology from biopsies categorised into Gleason score is the only confirmatory test for cancer diagnosis and is 
most commonly used for risk stratification of men with a recent diagnosis of prostate cancer. Based on this men 
are counselled for various treatment options. MR imaging data is not considered in risk stratification at present. 
With increasing therapeutic options available to men with a diagnosis of prostate cancer, scrutiny of informa-
tion from biopsy grade becomes increasingly important. There is around 35.5% (range: 14–51%) upgrading of 
biopsy GS on LRP1. Many factors contribute to the discrepancy between needle biopsy and corresponding radical 
surgery GS. Under calling of Gleason cribriform Gleason pattern 4 as pattern 3 or the presence of borderline 
grades due to barely appreciable glandular differentiation under microscope and lack of sampling of tertiary 
grade disease on biopsies are known contributors. Factors such as age, size of prostate, extent of cancer on biopsy 
needle and number of biopsy samples (extended/ or mapping) have also been known to impact on the incidence 
of upgrading2.
In light of a number of studies reporting upgrading or under-grading of prostate cancer on needle biopsies, 
there is the potential for under treatment or overtreatment (i.e. radiotherapy and hormone duration). Several 
publications3,4 and consensus updates on the Gleason grading system have partially addressed this issue including 
recommendation of deriving GS by adding the most common and highest Gleason pattern on biopsy rather than 
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original method of adding the primary and second most common patterns5. Moreover, upgrading if suspected, 
has long-term outcome implications. Corcoran et al.6 have shown that even after adjusting for known preoper-
ative variables (including clinical stage, prostate-specific antigen (PSA), number of positive cores and percent-
age of positive cores) upgrade to a higher Gleason Score (GS) remained a strong and independent predictor of 
biochemical recurrence after attempted local curative therapy, this underscores the importance of gaining more 
information to predict upgrading of biopsy GS in men diagnosed with prostate cancer as this may serve as a 
marker of biologically aggressive disease.
Pre-biopsy MRI has recently been shown to hold great promise in the detection and characterisation of pros-
tate cancer7. A negative scan (no lesion seen on the MRI scan) showed a high negative predictive value for the 
presence of significant prostate cancer8. Song et al.9 reported a high predictive value of PIRADS v2 in predicting 
upgrading of GS from biopsy, however this study was retrospective and MR Imaging was obtained at least 3 weeks 
following biopsies - an approach known to impact interpretation of images. Post-biopsy haemorrhage is the most 
common false-positive finding for prostate cancer10. In this study, there was no attempt to align histopathological 
sectioning to MRI using recently reported 3D-mould technology. Therefore, this is the first report describing 
predictive accuracy of pre-biopsy MRI in upgrading biopsy GS following LRP using patient-specific 3D moulds 
to ensure permitted alignment of excised prostates with MRI scans.
patients and methods
Study population. This is a study with prior Caldicott institutional approval (Caldicott/IGTCAL5626). All 
experiments including the study protocol study followed approved institutional guidelines. The study had ethi-
cal approval (14/ES/1070) with each participant informed consenting to the use of their imaging data. Between 
July 2014 and January 2019, 330 men consecutively treated by LRP who were diagnosed with localised pros-
tate cancer with raised PSA or/and abnormal digital rectal examination were included in this study. They were 
offered mpMRI and those with positive MRI results (PIRADS score 3 and above) were performed transrectal 
ultrasound (TRUS)-guided prostate biopsy (12 cores) followed. Of these patients, eight were excluded because 
of contraindication to MRI such as a heart pacemaker and metallic foreign body including three claustrophobic 
patients. Further analysis included remaining 322 patients (Fig. 1). The clinical, pathological and imaging factors 
information of the patients, including age, weight, preoperative PSA, PSA density, number of positive cores, max-
imum percentage of cancer per core and PIRADS v2 score on multiparametric MRI (mpMRI) were recorded. GS 
upgrading defined as a biopsy GS increasing from lower to higher grade on reported before2. Table 1 summarises 
the baseline characteristics between upgraded and non-upgraded groups of the cohort.
Hypotheses of the study. We hypothesised that pre-biopsy MRI with PIRADS classification of suspicious 
area in prostatic cancer improve prediction of GS upgrading from biopsy to radical prostatectomy. Upgrading 
of GS on histology was defined as change of GS from lower to higher grade between biopsy and histology from 
radical prostatectomy.
MRI protocol and PIRADS score. All patients’ mpMRI scans were performed on 3 T scanner (TIM Trio, 
Siemens, Erlangen, Germany) 2 weeks before TRUS-guided biopsies. The mpMRI protocol was derived from 
the European Society of Uro-radiology Guidelines 2012 for the detection of prostate cancer and the subsequent 
Figure 1. Flowchart of the study.
3Scientific RepoRtS |         (2020) 10:7722  | https://doi.org/10.1038/s41598-020-64693-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
publication of version 211. Table 2 briefly summarizes the MRI acquisition parameters. Localiser images were 
acquired in all three imaging planes, whereby the plane of the prostate was defined in relation to the rectal wall.
The mpMRI images were analysed and scored by experienced uro-radiologists using PIRADS v2.0; and the 
radiologists were blinded to all patients’ pathology results. PIRADS v2.0 assessment categories were described as 
follows: score 1, clinically significant cancer is highly unlikely to be present; score 2, clinically significant cancer 
is unlikely to be present; score 3, the presence of clinically significant cancer is equivocal; score 4, clinically signif-
icant cancer is likely to be present; and score 5, clinically significant cancer is highly likely to be present (Fig. 2).
Histopathology data and analysis. The biopsy results were analysed by experienced pathologists; who 
were blinded to MRI findings. The GS for each patient was obtained. The radical prostate specimens for histology 
were sliced in patient-specific moulds to aid orientations between imaging and histology, which were fabricated 
using a 3D printer as described by our group and others previously12,13. Specifically, patient specific 3D printed 
moulds were made prior to surgery based on the T2-weighted MRI prostate capsule the moulds were customised 
for each patient using MIMICS and Solidworks. Moulds were printed at 200 micro resolution using a consumer 
grade 3D printer (MakerBot Replicator 5th generation). The average mould required 120 minutes to design, 4 to 
7 hours to print and an expense for materials of less than $712.
Statistical analysis. Baseline characteristics of patients and pathological outcomes were compared using 
a chi-square test for categorical data (PIRADS score) and a Student t-test or ANOVA for continuous data (age, 
weight, PSA level, PSAD, number of positive cores and maximum percentage of cancer per core). Univariate 
logistic regression was applied to investigate the association of clinical variables with the upgrading of biopsy GS. 
Variables with P < 0.05 in the univariate analysis were further assessed using a multivariate logistic regression 
analysis to identify factors predictive of GS upgrading. In order to estimate the area under the curve (AUC) for 
predicting GS upgrading to determine the diagnostic performance of clinical variables with or without PIRADS 
score, a receiver operating characteristic (ROC) curve analysis was conducted.
In addition, logistic regression model coefficients were used to perform a nomogram predicating the probabil-
ity of GS upgrading. Non-informative or non-significant variables in univariate logistic regression for GS upgrad-
ing were removed. The value of concordance indexes (c-index) were calculated and compared. The bias-corrected 
calibrated values were generated from internal validation based on 200 bootstrap resamples.
A decision-analysis curve was constructed assessing impact of nomogram using different thresholds probabil-
ities of upgrading (none of the GS upgrade to all GS upgrade).
Number of patients
Total Upgrading No upgrading
322 102 220
Age (y), mean ± SD (range) 66.83 ± 5.9(44–77) 66.82 ± 6.12(49–77) 66.85 ± 5.9(44–77)
Prostate Weight mean ± SD (range) 63.7 ± 30.13(12–207) 65.3 ± 26.2(20–155) 63.1 ± 31.78(12–207)
PSA level (ng/ml), mean ± SD (range) 11.1 ± 7.39(0.1–47.7) 12.6 ± 9.98 (2–47.7) 10.39 ± 5.7(0.1–41)
PSA Density (ng/ml2), mean ± SD (range) 0.261 ± 0.234 (0.001–3.48) 0.212 ± 0.183(0.035–1.11) 0.203 ± 0.254(0.00198–3.48)
Number of positive cores 4.8 ± 3.4(1–12) 4.1 ± 3.07(1–12) 5.08 ± 3.42(1–12)
Maximum percentage of cancer per core 50.2 ± 30.4(5–100) 42.5 ± 30.6(5–100) 53.3 ± 29.52(5–100)
PIRADS from mpMRI Benign (1,2) 17 (5%) 4 (4%) 13 (6%)
PIRADS 3 21 (7%) 6 (6%) 15(7%)
PIRADS 4 78 (24%) 26 (26%) 52 (23%)
PIRADS 5 206 (64%) 66 (65%) 140 (64%)
Table 1. Patient characteristics.
T1WI High resolution T2WI DWI DCE
Axial Sagittal Axial Coronal DWI DWI high b-value Dyn Gd-MRI
TR (ms) 650 6000 4000 5000 3300 3300 4.76
Sequence 2DTSE 2DTSE 2DTSE 2DTSE 2DEPI 2DEPI 3D VIBE
TE (ms) 11 102 100 100 95 95 2.45
Flip angle (°) 150 140 150 150 — — 10
Slice thickness (mm) 3 3 3 3 3 3 3
Slice gap (mm) 0.6 0.6 0.6 0.6 0 0 0.6
Resolution (pixels) 320 320 320 320 192 192 192
FOV (mm) 200 200 200 200 280 280 280
b-values (s/mm2) — — — — 50,100,500,1000 2000 —
Temporal resolution (s) — — — — — — 4
Table 2. MRI acquisition parameters.
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Analyses were performed using SPSS 22 (IBM Corporation, New York, US) and R software. The alpha level 
was set at 0.05 to determine two-tailed significance.
Results
Upgrading cohort characteristics. In total, 322 men were included in our study. Table 3 shows the con-
cordance between the biopsy and prostatectomy Gleason score sums. Of these, (102/322; 31.6%) had GS upgrad-
ing from biopsy to LRP. Almost half of this upgrading was from biopsy GS ≤ 6 disease (56/102; 55%). More than 
half of whole cohort (175/322; 54%) had a GS 7 on prostate biopsy and (30/175; 17%) men had GS upgrading. 
Finally, eighty five of the cohort (85/322; 26%) had a GS ≥ 8 on prostate biopsy and (16/85; 18.8%) men had GS 
upgrading from GS 8 on prostate biopsy to GS > 8 at LRP.
The correlation between PIRADS score and pathologic GS at LRP is demonstrated in Fig. 3. Of the 322 
patients, the distribution of PIRADS score was as follows: score 1 and 2 in 17 (17/322; 5%) patients, score 3 in 21 
(21/322; 7%) patients, score 4 in 78 (78/322; 24%) patients, and score 5 in 206 (206/322; 64%) patients.
Predictions of GS upgrading. Table 4 shows the outcomes of the logistic regression analysis and predictive 
variables of GS upgrading. On univariate analyses, increased preoperative PSA levels, number of positive cores, 
maximum percentage of cancer per core and PIRADS ≥ 4 were all significantly associated with GS upgrading 
(p < 0.05). Age, weight of prostate and PSAD did not show any significance (p > 0.05) which were excluded from 
further analyses. In the multivariate analyses, PIRADS ≥ 4 and higher PSA level were both statistically significant 
and independently predictive of GS upgrading (p = 0.001 and 0.003, respectively).
In Fig. 4, PIRADS v2 score with PSA value show a higher accuracy than PSA alone for predicting GS upgrad-
ing (AUC = 0.90 and 0.64, respectively, p < 0.001).
Impact of PIRADS score on prediction of GS upgrading in relation to other factors. Figure 5a1,a2 
show the nomograms constructed for upgradation of biopsy GS with and without PIRADS v2 score data. Longer 
scales indicated higher percentage of impact and larger points were suggesting probability of upgrading. PIRADS 
score had the greatest impact followed by PSA level.C-index of the established nomogram which had PIRADS 
v2 score variable to predict the GS upgrading in the cohort was significantly higher than that of the nomogram 
Figure 2. (a) A 73 year-old man with Gleason score 6 disease on prostate cancer on TRUS-Guided biopsies. (b) 
The grade was upgrading to GS 7 on whole mount radical prostatectomy specimen (c) Axial T2-wighted image 
shows ill-defined homogeneous low-signal-intensity on the central zone (d), Apparent diffusion coefficient 
(ADC) shows restricted diffusion in low-signal mass and (e) dynamic contrast enhanced (DCE) shows fast and 
strong enhancement and early contrast agent washout (type 3 curve), (e,f) The lesion was scored as PIRADSv2 5 
(>1.5 cm) and based on parameters described here.
Biopsy 
Gleason sum
Radical prostatectomy Gleason sum
Total6 7 8 9–10
1–5 0 3 0 1 4
6 6 46 2 4 58
7 0 145 14 16 175
8 0 19 9 16 44
9–10 0 2 3 36 41
Total 6 215 28 73 322
Table 3. Comparison between biopsy and radical prostatectomy Gleason score sum.
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without PIRADS score (0.90 [95% CI 0.87–0.89] vs. 0.64 [95% CI, 0.57–0.70], p = 0.001). The nomograms were 
then validated using 200 bootstrap samples, internal calibration curves are shown in Fig. 5b1,b2.
Decision curve analysis. The decision analysis curve is shown in Fig. 6. The net benefit for the model using 
PIRADS score was significantly higher at all thresholds compared with the model without PIRADS score. As 
seen in Fig. 6, the decision curve line (depicted by a red line) of the model without the PIRADS scores remained 
close to the line with threshold probabilities ranging from 0 to 0.25. In contrast, a higher positive net benefit was 
obtained in the range of threshold probabilities ranging from 0.05 to 1.0 in the model with PIRADS scores.
Discussion
Principal findings of the study. This is the first study to bring together information of PIRADS scores in 
pre-biopsy MRI and an improved image oriented histopathological grossing of RP specimen by making the use of 
the mould, bridging the gap in the existing literature. Our results indicate a significant advantage (C-index 0.90 vs 
0.64) of using the prediction model including PIRADS scores added to conventional clinic-pathological charac-
teristics (PSA level, percentage of cancer on core-biopsies, gland size etc.) of men with prostate cancer confirmed 
by systematic transrectal random biopsies relative to a model without PIRADS scores. Prostate biopsy GS upgrad-
ing remains a challenge for physicians managing localised prostate cancer, as better knowledge of contributing 
factors and how to narrow the gap is lacking2. To inform any consensus, we need an improved understanding of 
the role imaging can play, in particular pre-biopsy MRI, in predicting GS change and adverse downstream onco-
logical outcomes. Although, recent improvements have been made in refining biopsy strategies and in reducing 
sampling errors, a significant and continued effort is still needed to identify men at risk of GS upgrading.
Study findings in context of the reported literature. Wang JY et al.14 reported a nomogram with 
C-index of 0.795 using preoperative factors without imaging data in a non-screened population from China. 
This is similar to our study as the healthcare system for the cohort reported here did not have men screened for 
prostate cancer. Table 5 shows the predictive ability of various reported nomograms in upgrading of biopsy GS 
of prostate cancer in screened populations1,14–17. The upgrading rate of biopsy GS seen in our cohort is similar to 
a larger cohort of 2982 patients reported previously15. A higher percentage of men with a GS of 6 were upgraded 
in the present study. It is interesting that despite the higher number of cores obtained in the present study (12 in 
Figure 3. Radical prostatectomy Gleason score stratified according to PIRADS score.
Univariate Multivariate
OR (95% CI) P-value OR (95% CI) P-value
Age 1.005 (0.962–1.041) 0.799
Pathology weight 1.002(0.931–1.009) 0.540
Number of positive cores 0.86(0.87–0.96) 0.005 0.970(0.98–1.01) 0.69
PSA level (ng/ml) 1.040 (1.009–1.073) 0.001 1.09(1.030–1.160) 0.003
PSA Density (ng/ml2) 1.15 (0.44–3.04) 0.76
Maximum percentage of 
cancer per core 0.988 (0.980–0.96) 0.002 0.970 (0.84–1.12) 0.62
PIRADS
 ≤ 3 1 (reference) — 1 (reference) —
 > 3 0.017(0.08–0.04) 0.001 0.014 (0.06–0.034) 0.001
Table 4. Univariate and multivariate logistic regression analysis.
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number) in comparison with 6–10 biopsy cores obtained in study by Chun FK et al.15; upgrading rates remain 
comparable.
A number of previous studies have carried out multivariate analyses of factors responsible for upgrading 
of biopsy GS including construction of nomograms (Table 5). In predictive oncology, nomograms have huge 
Figure 4. Receiver operating characteristic (ROC) curve of the clinical variables with and without PIRADS 
score.
Figure 5. The nomograms of Gleason score upgrading prediction with (a1) and without PIRADS score (a2). 
Calibration plots of observed and predicted probability of GS upgrading with (b1) and without PIRADS score 
(b2).
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potential to help clinicians determine the risk of disease progression and identify those who would experience 
a greater benefit from multimodality therapy. This approach may result in avoiding unnecessary treatment and 
improve quality of life by reducing side effects of therapy through better and more precise approach. However, a 
careful approach is needed to construct nomogram based on specific question, the study population, the method 
of construction, and its ability to apply to a particular clinical situation. We have followed guidelines described in 
previous publications18–20 in constructing nomogram in this study including selection of variables and statistical 
methods. The nomogram in the present study has been internally validated (Cross-validation and bootstrapping). 
External validation of nomogram was not carried out in the present study as this would require further prospec-
tive multi-centre recruitment of a cohort. Since D’Amico pioneered this approach21, none of the reported predic-
tive nomograms have included imaging features of the disease. Furthermore, the advantage of our nomogram is 
a higher overall accuracy (discriminant properties) and closer agreement between predicted and observed values 
(superior calibration). Estimating clinical utility of nomograms in prognosticating an outcome of intervention 
remains core value of translational research in precision medicine. Vickers and Elkin22 have introduced decision 
analysis curves estimating probabilities of benefits and harms that a diagnostic test or intervention can trigger at 
various thresholds. Addition of PIRADS score to nomogram achieved a higher net benefit of decisions making 
in comparison to leaving out PIRADS score as shown in the decision analysis curve constructed in the present 
study. The thresholds ranged from no upgrading of disease to all men having upgrading of disease following LRP.
Clinical implications of the study findings. Predicting final histopathological Gleason score of prostate 
cancer remains a highly desirable information for physicians counselling men with localised prostate cancer 
for various modalities of treatment and long-term disease recurrence. At present, various nomograms are used 
mainly taking into consideration clinical factors such as age, pre-operative PSA level and number of biopsy cores 
involved with the cancer. Notwithstanding this, there is still a large histopathological discrepancy between biopsy 
and final radical prostatectomy Gleason score. The present study reports a nomogram based on pre-biopsy mul-
tiparameteric MRI grade (PIRADS score) of cancer alongwith other known clinical parameters. The nomogram 
clearly showed an improved prediction of final Gleason score and the findings have a large implications for cli-
nicians and researchers in this area. We envisage that this and further research should take us close to precise 
prediction of final Gleason score of histopathology in prostate cancer and thereby an improved and informed 
decision making by stakeholders including patients in the management of localised prostate cancer. This will have 
huge benefits for improved GS prediction for men opting for active surveillance and focal therapy besides those 
opting for radical prostatectomy.
Figure 6. Decision analysis demonstrated a high net benefit of PIRADS score model across a wide range of 
threshold probabilities. Prediction model without PIRADS score (red line); prediction model with PIRADS 
score (blue line).
Author year Number of patients Performance (C-index) Significant parameters on multivariate analysis
Chun, FK 2006 2982 0.804 PSA level, clinical stage and primary and secondary GS
Kulkarni, GS 2007 175 0.71 PSA level and the level of pathologist expertise
Budäus, L 2010 414 0.708 PSA level, clinical stage, prostate volume and percent of positive cores
Wang, JY 2014 220 0.789 PSA level, clinical stage, and primary and secondary GS
Biming, He 2016 411 0.753 Primary and secondary GS and obesity
This study 2019 322 0.90 PSA level and PIRADS score on mp-MRI
Table 5. literature review and comparison between previous and current studies.
8Scientific RepoRtS |         (2020) 10:7722  | https://doi.org/10.1038/s41598-020-64693-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
Limitation of the study. There are limitations to our study. This is a single centre study with dedicated 
uro-radiologist and pathologist, and the rate of upgrading may be different in small centres. Moreover, overall 
accuracy of our model, although higher than previous was not perfect (90%). Additionally, performance of our 
model needs further validation in an external data set. Finally, the accuracy of our model could still be improved 
by integrating additional predictor variables, such as the novel genomic and other biomarkers23,24. The growing 
field of artificial intelligence and machine learning using radiomics approach may improve our ability to define 
tumour characteristics and classification. This, undoubtly may impact results of the study in the future. Finally, 
with emerging evidence supporting MRI facilitated biopsy targeting of suspicious areas using ultrasound, the 
rate of upgrading and the future implications for the practice may change25. There is an emerging evidence that 
targeted biopsy may improve our ability to narrow the upgrading gap between the biopsies and radical prosta-
tectomy histology26,27; however no predictive nomogram information was available from both the studies. Our 
ongoing work through randomised intervention in MR/US fusion should be able to provide more information28
In Conclusions, PIRADS version 2 score of 4 or 5 are associated with an increased risk of biopsy Gleason Score 
upgrading. Pre-biopsy MRI and PIRADS score significantly and independently predict GS upgrading. If proven 
by external validation, this information should help in decision making by offering treatment options to men with 
localised prostate cancer.
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